For Immunotherapy Research: Pre-made Oncolytic Virus Products Available at Creative Biolabs

To advance oncolytic virotherapy research, Creative Biolabs has built the oncolytic virus engineering platform, and updated the list of pre-made oncolytic virus products, which are of high quality and are ready-to-transfect.

New York, USA – September 28, 2021 – Oncolytic viruses (OVs), a kind of viruses that can replicate in tumor tissues, and kill tumor cells, represent an important new tool in weaponizing the human immune system to fight cancer as two OV drugs have been marketed globally, and many more are in the research and development stage.

Supported by cutting-edge technology platforms and years of experience in immunotherapy, Creative Biolabs has integrated a package of pre-made oncolytic virus products, covering the most researched type of genetically-engineered herpes simplex virus (HSV), adenovirus (AdV), vesicular stomatitis virus (VSV), and vaccinia virus (VACV), to facilitate related research on the innovative treatment of melanoma, breast cancer, ovarian cancer, etc.

• Reporter-encoding Oncolytic Virus

Reporter-encoding oncolytic viruses allow accurate tracking of gene expression, tumor metastases, viral infection, and assessment of gene therapy. Creative Biolabs has released a series of purified reporter-encoding OVs, including herpes simplex virus and vaccinia virus.

Featured products:

Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), SV40-GFP

Reporter-encoding Oncolytic Vaccinia Virus Western Reserve (ΔE3L,ΔK3), pSE/L-(Dsred)

• Cytokine-expressing Oncolytic Virus

Research has shown that the oncolytic efficacy of OVs can be enhanced through the expression of therapeutic transgenes like cytokines. Creative Biolabs has built an advanced OV engineering platform which provides a series of purified cytokine-expressing OV products.

Featured products:

Cytokine-expressing Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-IL-15

Cytokine-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L,ΔK3L), pSE/L-(mLIGHT)

Besides, the product portfolio also ranges from immune checkpoint antibody-armed OVs, capsid-modified OVs, miRNA-regulated OVs to oncolytic adenovirus construction kits (double-armed oncolytic adenovirus construction kit, capsid-modified oncolytic adenovirus construction kit, miRNA-regulated oncolytic adenovirus construction kit).

To facilitate oncolytic virus therapy development, Creative Biolabs ensures accurate design and construction, and manifold functional validations, and the scientist team can also help design customized products if there are any specific demands.

“Oncolytic virus therapy is a revolutionary cancer treatment tool that has shown encouraging results over the last 20 years. Currently, the main challenges for this therapy are targeted delivery, and combination therapy with other therapies. And we will be a reliable partner to advance your research on unleashing more potential of oncolytic virus,” said a senior scientist at Creative Biolabs.

Detailed information can be found on

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers oncolytic virus engineering, in vitro validation study, in vivo preclinical study, animal models for oncolytic virus study, disease-specific oncolytic virotherapy development, etc.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States